Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FINAL DATA FROM VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY CONSISTENT WITH PREVIOUSLY REPORTED POSITIVE INTERIM DATA; PROVIDE ADDITIONAL EVIDENCE SUPPORTING HIGHER VAX-31 DOSES BEING EVALUATED IN ONGOING INFANT PHASE 2 STUDY

VAXCYTE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE INCLUDING FINAL DATA FROM POSITIVE VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY

NEW AGREEMENT WITH THERMO FISHER SCIENTIFIC EXPANDS DOMESTIC CAPACITY TO SUPPORT FUTURE COMMERCIAL MANUFACTURING OF VAXCYTE'S BROAD-SPECTRUM PNEUMOCOCCAL CONJUGATEVACCINE CANDIDATES

VAXCYTE TO ESTABLISH FILL-FINISH MANUFACTURING IN NORTH CAROLINA AS KEY ELEMENT OF LONG-TERM UNITED STATES COMMERCIAL SUPPLY STRATEGY REPRESENTING UP TO $1 BILLION IN MANUFACTURING AND SERVICES

VAX-31 OPTIMIZED DOSE, WITH MAJORITY OF SEROTYPES DOSED AT 4.4MCG AND BALANCE AT 3.3MCG, IS DESIGNED TO ELICIT EVEN STRONGER IMMUNE RESPONSES IN INFANT POPULATION TO PROTECT AGAINST INVASIVE PNEUMOCOCCAL DISEASE (IPD)

VAXCYTE ADVANCES VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY WITH FIRST PARTICIPANTS RECEIVING VAX-31 OPTIMIZED DOSE

FOLLOWING INTERACTIONS WITH FDA ON VAX-31 ADULT PROGRAM, INCLUDING END-OF-PHASE 2 MEETING, COMPANY FINALIZING PHASE 3 CLINICAL PROGRAM TO VALIDATE VAX-31 AS POTENTIAL NEW STANDARD-OF-CARE ADULT PCV ; PIVOTAL, NON-INFERIORITY STUDY EXPECTED TO BE INITIATED IN FOURTH QUARTER OF 2025 WITH TOPLINE DATA IN 2026 FDA PROVIDED INPUT ON VAX-31 ADULT CMC LICENSURE REQUIREMENTS FACILITATING PROGRESSION TO PHASE 3; COMPANY PLANS TO SEEK ONGOING INPUT AS PROGRAM ADVANCES COMPANY EXPECTS MULTIPLE VAX-31 ADULT PHASE 3 PROGRAM DATA READOUTS IN 2026 AND 2027 TO SUPPORT BIOLOGICS LICENSE APPLICATION SUBMISSION FOR VAX-31 PEDIATRIC PROGRAM, COMPANY MODIFIES ONGOING INFANT PHASE 2 DOSE-FINDING STUDY TO ADD A VAX-31 OPTIMIZED DOSE ARM (4.4MCG/3.3MCG) AND DISCONTINUES ENROLLMENT OF LOW DOSE ARM; ENROLLMENT IN MODIFIED STUDY EXPECTED TO PROCEED BY END OF THIRD QUARTER OF 2025 WITH TOPLINE DATA FROM BOTH PRIMARY IMMUNIZATION SERIES AND BOOSTER DOSE BY END OF FIRST HALF OF 2027 COMPANY REMAINS FOCUSED ON DISCIPLINED CAPITAL ALLOCATION; STREAMLINING EARLY-STAGE PIPELINE TO PRIORITIZE RESOURCES FOR PCV PROGRAMS AND FURTHER EXTEND CASH RUNWAY APPROXIMATELY $2.8 BILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2025 SAN CARLOS, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY ENGINEERING HIGH-FIDELITY VACCINES TO PROTECT HUMANKIND FROM THE CONSEQUENCES OF BACTERIAL DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE, HIGHLIGHTING KEY CLINICAL AND REGULATORY PROGRESS FOR VAX-31, A POTENTIAL BEST-IN-CLASS PNEUMOCOCCAL CONJUGATE VACCINE (PCV).

VAXCYTE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE, HIGHLIGHTING KEY CLINICAL AND REGULATORY PROGRESS FOR VAX-31, A POTENTIAL BEST-IN-CLASS PNEUMOCOCCAL CONJUGATE VACCINE (PCV)

-- COMPANY REPORTED POSITIVE TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PHASE 2 DOSE-FINDING STUDY OF VAX-24 IN HEALTHY INFANTS; BALANCE OF DATA EXPECTED BY END OF 2025 -- -- INITIATED SECOND AND FINAL STAGE OF VAX-31 INFANT PHASE 2 DOSE-FINDING STUDY; TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY THREE-DOSE IMMUNIZATION SERIES EXPECTED IN MID-2026, WITH COMPLETE BOOSTER DATA UP TO NINE MONTHS LATER --

VAXCYTE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN CARLOS, CALIF., MAY 01, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A VACCINE INNOVATION COMPANY ENGINEERING HIGH-FIDELITY VACCINES TO PROTECT HUMANKIND FROM THE CONSEQUENCES OF BACTERIAL DISEASES, TODAY ANNOUNCED IT HAS APPOINTED DR. OLIVIER BRANDICOURT, A VETERAN BIOPHARMACEUTICAL INDUSTRY EXECUTIVE AND THE FORMER CHIEF EXECUTIVE OFFICER OF SANOFI S.A., TO ITS BOARD OF DIRECTORS.

VAXCYTE APPOINTS DR. OLIVIER BRANDICOURT TO BOARD OF DIRECTORS

-- AT ALL DOSES EVALUATED, VAX-24 WAS WELL-TOLERATED AND DEMONSTRATED A SAFETY AND TOLERABILITY PROFILE SIMILAR TO PREVNAR 20 (PCV20)-- -- AT ALL DOSES EVALUATED, VAX-24 ELICITED SUBSTANTIAL IMMUNE RESPONSES FOLLOWING PRIMARY THREE-DOSE IMMUNIZATION SERIES; TOPLINE RESULTS ALSO INCLUDE INTERIM BOOSTER DOSE IGG DATA SHOWING ROBUST MEMORY RESPONSES ACROSS ALL DOSES -- -- DOSE-DEPENDENT IMMUNE RESPONSES CONSISTENTLY DEMONSTRATED AND LITTLE TO NO EVIDENCE OF CARRIER SUPPRESSION WAS OBSERVED, SUPPORTING PLATFORM'S POTENTIAL TO DELIVER BROADEST-SPECTRUM INFANT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) CANDIDATES -- -- COMPANY SELECTS VAX-24 MID DOSE (2.2MCG) AS BASIS FOR OPTIMIZED DOSE FORMULATION FOR ADVANCEMENT TO POTENTIAL INFANT PHASE 3 PROGRAM, PENDING TOPLINE VAX-31 INFANT PHASE 2 STUDY READOUT -- -- COMPANY ANNOUNCES VAX-XL, THIRD-GENERATION PCV CANDIDATE DESIGNED TO FURTHER EXPAND SPECTRUM OF COVERAGE -- -- COMPANY TO HOST WEBCAST/CONFERENCE CALL TODAY AT 8:00 A.M. ET / 5:00 A.M.

VAXCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM VAX-24 INFANT PHASE 2 DOSE-FINDING STUDY

SAN CARLOS, CALIF., MARCH 30, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY ENGINEERING HIGH-FIDELITY VACCINES TO PROTECT HUMANKIND FROM THE CONSEQUENCES OF BACTERIAL DISEASES, TODAY ANNOUNCED IT WILL HOLD A WEBCAST AND CONFERENCE CALL TOMORROW, MARCH 31, 2025, AT 8:00 A.M. EASTERN TIME TO PRESENT TOPLINE RESULTS FROM THE VAX-24 INFANT PHASE 2 STUDY. THIS STUDY IS EVALUATING THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF VAX-24, THE COMPANY'S 24-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) CANDIDATE DESIGNED TO PREVENT INVASIVE PNEUMOCOCCAL DISEASE (IPD), COMPARED TO PREVNAR 20 IN HEALTHY INFANTS.

VAXCYTE TO HOST WEBCAST AND CONFERENCE CALL TO PRESENT TOPLINE RESULTS FROM VAX-24 INFANT PHASE 2 STUDY

-- COMPLETED SUCCESSFUL VAX-31 PHASE 2 ADULT PROGRAM; COMPANY REMAINS ON TRACK TO INITIATE VAX-31 ADULT PHASE 3 PIVOTAL, NON-INFERIORITY STUDY BY MID-2025 AND ANNOUNCE TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITYDATA IN 2026 -- -- COMPANY EXPECTS TO ANNOUNCE TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES OF VAX-24 INFANT PHASE 2 STUDY BY THE END OF FIRST QUARTER, FOLLOWED BY TOPLINE DATA FROM BOOSTER DOSE BY THE END OF 2025 --

VAXCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN CARLOS, CALIF., FEB. 12, 2025 (GLOBE NEWSWIRE) -- VAXCYTE, INC. (NASDAQ: PCVX), A CLINICAL-STAGE VACCINE INNOVATION COMPANY ENGINEERING HIGH-FIDELITY VACCINES TO PROTECT HUMANKIND FROM THE CONSEQUENCES OF BACTERIAL DISEASES, ANNOUNCED TODAY THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2024 AFTER MARKET CLOSE ON FEBRUARY 25, 2025. COMPANY MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST BEGINNING AT 4:30 P.M. ET / 1:30 P.M. PT THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

VAXCYTE TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON FEBRUARY 25, 2025

-- ADVANCEMENT TO STAGE 2 OF INFANT STUDY SUPPORTED BY REVIEW OF STAGE 1 SAFETY AND TOLERABILITY DATA -- -- COMPANY EXPECTS TO ANNOUNCE VAX-31 INFANT STUDY TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES IN MID-2026, FOLLOWED BY TOPLINE DATA FROM THE BOOSTER DOSE APPROXIMATELY NINE MONTHS LATER --

Vaxcyte, Inc.

PCVX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vaxcyte, Inc.

PCVX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PCVX